|3.||Breast Neoplasms (Breast Cancer)
|4.||Neoplasm Metastasis (Metastasis)
|1.||Sood, Anil K: 137 articles (12/2015 - 07/2002)|
|2.||Markman, Maurie: 100 articles (11/2015 - 02/2002)|
|3.||Sehouli, Jalid: 94 articles (12/2015 - 05/2002)|
|4.||Scambia, Giovanni: 91 articles (12/2015 - 01/2002)|
|5.||Vergote, Ignace: 78 articles (12/2015 - 01/2003)|
|6.||Berchuck, Andrew: 76 articles (02/2016 - 08/2002)|
|7.||Bast, Robert C: 75 articles (01/2016 - 12/2002)|
|8.||Coleman, Robert L: 68 articles (12/2015 - 01/2002)|
|9.||Ma, Ding: 68 articles (10/2015 - 04/2002)|
|10.||Cramer, Daniel W: 62 articles (12/2015 - 02/2002)|
|1.||Paclitaxel (Taxol)FDA LinkGeneric
02/01/2009 - "Paclitaxel is used in the first line treatment of ovarian cancer, but acquired resistance represents the most important clinical problem and a major obstacle to a successful therapy. "
09/01/2007 - "Both times, the paclitaxel dramatically improved the ovarian cancer. "
03/01/2004 - "Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian cancer. "
02/15/1995 - "Taxol has been called the best new anticancer agent developed from natural products, showing particular efficacy against ovarian cancer. "
08/01/1998 - "The correlation between high BAX levels and improved clinical outcome suggests that an intact apoptotic pathway is an important determinant of chemoresponsiveness in ovarian cancer patients who receive paclitaxel."
|2.||Cisplatin (Platino)FDA LinkGeneric
10/01/2015 - "In vitro cell line studies with herceptin-DGA-G4-cisplatin in HER-2 +ve and HER-2 -ve human ovarian cancer cell lines showed that these nanoparticles possessed remarkable features such as lower IC50 value, improved S-phase arrest, and enhanced apoptosis due to increased cellular uptake and accumulation than the untargeted DGA-G4-cisplatin and free cisplatin. "
12/01/2006 - "The markedly improved survival data resulting from a phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on intraperitoneal therapy in January, 2006, in San Diego, California. "
12/01/1985 - "These results demonstrate that the cisplatin dose is an important factor in achieving improved results in the treatment of ovarian cancer."
01/01/2001 - "Phase III trials employing intraperitoneal cisplatin as initial treatment of small volume advanced ovarian cancer have demonstrated that regional therapy results in a modest, but statistically significant, improvement in both progression-free and overall survival compared to intravenous cisplatin. "
07/18/2011 - "The drug-loaded particles show significantly greater toxicity toward human ovarian cancer cells (in vitro), relative to an equivalent quantity of free cisplatin. "
01/01/2006 - "By contrast, most studies indicate that women developing a BRCA1/2-related ovarian cancer have an improved survival compared with non-carriers, particularly if they receive platinum-based therapy. "
01/01/2014 - "Following elderly ovarian cancer patients over a lifetime using real-world longitudinal data and adjusting for quality of life, we found that treatment with platinum-based regimen was the most cost-effective treatment alternative."
01/01/2013 - "In women with platinum-sensitive recurrent ovarian cancer, ability to achieve surgery with complete cytoreduction (no visible residual disease) is associated with significant improvement in overall survival. "
01/01/1993 - "Platinum-containing regimens are very effective in the primary treatment of ovarian cancer. "
05/01/2014 - "The standard platinum-based treatment of previously untreated advanced ovarian cancer continues to evolve because despite high response rates to such first-line treatment, a majority of patients will experience relapse. "
|4.||Carboplatin (JM8)FDA LinkGeneric
01/01/2012 - "The results of this study have demonstrated for the first time that the approach of coupling IP administration with FRT liposomal delivery could provide significantly improved therapeutic efficacy of carboplatin in the treatment of metastatic ovarian cancer."
09/01/2013 - "regimen using carboplatin will be beneficial for patients with advanced ovarian cancer. "
11/01/1999 - "Efficacy of 51Cr-EDTA clearance to tailor a carboplatin therapeutic regimen in ovarian cancer patients."
07/01/1997 - "Carboplatin proved to be effective in patients with optimally debulked ovarian cancer. "
09/01/1995 - "CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. "
|5.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
05/01/2012 - "Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission."
02/01/1976 - "In about 50% of primarily inoperable stage 3 ovarian cancers, the random treatment with cyclophosphamide (Endoxan) results in a clinical remission. "
04/01/2015 - "This is the first trial that evaluated single-agent, low-dose cyclophosphamide in HGSOC, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. "
09/01/2012 - "Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study."
06/01/1990 - "Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer."
08/01/2011 - "Bevacizumab is an agent with a tolerable safety profile which was described to be effective in recurrent ovarian cancer in recent phase I and phase II trials. "
02/01/2015 - "Continued investigation of populations with ovarian cancer in whom the efficacy of treatment with bevacizumab is expected to be increased (or in whom QOL is expected to increase with use) is critical."
01/01/2015 - "Chemo + Bev becomes cost-effective with an ICER ≤ $100K in sensitivity analysis when the cost of bevacizumab is discounted >37.5% or the dose is reduced from 15 to 7.5 mg/kg, an effective dose in ovarian cancer. "
09/01/2014 - "Randomized ovarian cancer trials, including ICON7, have reported improved progression-free survival (PFS) when bevacizumab was added to conventional cytotoxic therapy. "
02/01/2013 - "The evidence provided from Phase III trials has supported the efficacy of bevacizumab in primary and recurrent ovarian cancer management. "
|7.||Doxorubicin (Adriamycin)FDA LinkGeneric
12/15/2014 - "This study indicates significant antitumor efficacy of 34.5ENVE alone, and in combination with doxorubicin against disseminated peritoneal ovarian cancer."
12/01/1998 - "Although doxorubicin is not currently popular as a primary agent in ovarian cancer, overviews of previous studies suggest that the inclusion of doxorubicin may have improved outcome. "
12/15/2014 - "Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer."
11/01/2009 - "This drug in combination with doxil has shown to improve outcome in relapsed ovarian cancer, compared with doxil alone. "
05/01/2007 - "The resultant nanosized systems improved the uptake and cytotoxicity of doxorubicin in the ovarian cancer cells, OVCAR-3, with statistical significance. "
|8.||Topotecan (Hycamtin)FDA LinkGeneric
03/01/2009 - "The peer-reviewed literature reports that topotecan is an effective, well tolerated treatment option for relapsed ovarian cancer."
03/01/2005 - "Intraperitoneal administration of topotecan as consolidation therapy in patients with ovarian cancer has shown promising results. "
03/01/1996 - "Trial of topotecan as first-line treatment for ovarian cancer announced."
08/01/2005 - "Weekly topotecan may be an appropriate treatment option for patients with recurrent ovarian cancer, especially heavily pretreated patients who might require dosing schedules with improved tolerability."
12/01/2004 - "To retrospectively investigate the safety and efficacy of weekly topotecan in heavily pretreated patients with ovarian cancer. "
11/13/2005 - "Some chemotherapeutic combinations with gemcitabine for the first line treatment of ovarian cancers are also known and they were found to be superior to the multi-line treatments (81.6 +/- 17.9% complete remission on average with the former). "
01/01/2013 - "Together, our results suggest that gemcitabine is effective in decreasing double minute chromosomes and this affects the biology of ovarian cancer cells. "
04/10/2015 - "Despite diminution of hCNT1 transport in the majority of ovarian cancers and apparent trafficking defects with CCC, the chemotherapeutic efficacy of gemcitabine was broadly enhanced in all subtypes when delivered via engineered nanoparticles (NPs). "
01/01/2003 - "Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients."
09/01/2008 - "Our study aimed to investigate if p38-MAPK determined in primary ovarian cancer can serve as a predictive marker for sensitivity to gemcitabine treatment in recurrent disease. "
|10.||Biological Markers (Surrogate Marker)IBA
01/01/2012 - "Breast and ovarian cancer are the most common and lethal malignancies in women, respectively, and potential glycan biomarkers hold promise for early detection and targeted therapies. "
02/15/2008 - "In this study, we characterize and validate the combination of six serum biomarkers that discriminate between disease-free and ovarian cancer patients with high efficiency. "
10/01/2012 - "Ultimately, personalized therapy using novel biomarkers in parallel with improved early detection techniques could significantly enhance the prognosis of ovarian cancer patients."
01/01/2013 - "Understanding the underlying tumorigenesis and progression in ovarian cancer through the global view of interactions within/between different levels of genomic data is expected to provide guidance for improved prognostic biomarkers and individualized therapies."
01/01/2008 - "More importantly, the proposed approach shows promising results to infer novel biomarkers for ovarian cancer and extend current knowledge."
|1.||Drug Therapy (Chemotherapy)
04/01/2010 - "OBJECTIVE.: Despite advances in chemotherapy and radical surgery, most advanced stage ovarian cancer patients die from their disease, highlighting the need for the development of novel treatment strategies. "
06/01/2004 - "Radical surgery associated with early postoperative chemotherapy followed by systemic chemotherapy in the treatment of ovarian cancer makes it possible to achieve the best survival results and long periods of disease free."
01/01/2002 - "While most patients with advanced ovarian cancer can achieve prolonged remission with surgery and chemotherapy, eventually most will recur. "
11/01/1992 - "The results of the neurophysiologic examinations performed before and immediately after chemotherapy suggest that these schedules besides being safe and effective in the treatment of the ovarian cancer, have an extremely low peripheral neurotoxicity."
09/01/1990 - "1) Importance of chemotherapy in the treatment of advanced ovarian cancer: The most important factor for the cure of advanced ovarian cancer is the efficacy of the regimen used. "
|2.||Heterologous Transplantation (Xenotransplantation)
10/01/2006 - "This new xenograft model accompanied by noninvasive imaging is highly reproducible and likely to be very useful in testing new treatment strategies for ovarian cancer."
01/01/2005 - "Results indicated significant growth inhibitory activity of the transgenic factor in a human umbilical vein endothelial cell proliferation assay in vitro and protection against the growth of an angiogenesis-dependent human ovarian cancer cell line, SKOV3.ip1, xenograft in vivo with increased disease-free survival. "
01/01/2015 - "These results suggest that combination of a selective EGFR inhibitor and a PARP inhibitor is effective in ovarian cancer A2780 xenografts, and depends on enhanced autophagy."
03/01/2006 - "Further, therapeutic efficacy was evaluated in vivo using human ovarian cancer xenograft mouse models. "
02/01/1992 - "Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model."
|3.||Combination Drug Therapy (Combination Chemotherapy)
07/01/1995 - "The best treatment results for advanced-stage ovarian cancer patients are obtained with cytoreductive surgery followed by combination chemotherapy. "
04/01/2001 - "Cytoreductive surgery followed by combination chemotherapy results in an approximately 75% complete remission rate in patients with advanced ovarian cancer. "
12/01/1991 - "Adjuvant combination chemotherapy is beneficial for selected patients with early-stage ovarian cancer who are at high risk for failure after surgical treatment alone."
12/01/2011 - "Cytoreductive surgery and empirical combination chemotherapy have improved 5-year survival for ovarian cancer patients, but have not increased the overall rate of cure. "
07/15/1983 - "We conclude that this four-drug regimen is effective in the treatment of relapsing ovarian cancer patients and should be considered for study as a front-line combination chemotherapy for previously untreated patients."
11/01/2000 - "Because most options for ovarian cancer prevention are not highly efficacious, many high-risk women consider the option of bilateral prophylactic oophorectomy (BPO), in the hope that removal of healthy ovarian tissue will reduce their risk of developing invasive malignancy. "
11/01/1991 - "This article presents the background, rationale, and structure of the Yale Early Detection Program for ovarian cancer, whose goals are to identify the best techniques for diagnosing ovarian cancer in an early stage, to determine the frequency with which such tests should be employed, to assess false-positive results, and to identify women who might benefit from prophylactic oophorectomies."
09/01/2010 - "If proven effective, this technique can be useful in screening women at high risk of developing ovarian cancer to determine whether oophorectomy is necessary."
07/10/2007 - "Because of limitations in the efficacy of available screening and chemopreventive approaches for women with a mutation in one of these genes, surgical risk reduction, particularly risk-reducing salpingo-oophorectomy (RRSO), has become an important component of the management options in hereditary breast-ovarian cancer syndrome. "
04/01/2009 - "Risk-reducing salpingo-oophorectomy (RRSO) provides effective protection against ovarian cancer in BRCA mutation carriers and in women at risk for hereditary breast ovarian cancer, but little is known about non-oncologic morbidity after the procedure. "
10/01/2014 - "Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model."
07/01/1997 - "The favorable physical characteristics of 186Re as well as its efficacy when conjugated to a MAb indicate 186Re as an attractive radionuclide in radioimmunotherapy of ovarian cancer patients."
01/01/2010 - "The aim of this study was to investigate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. "
08/01/2009 - "The aim of this study was to investigate the therapeutic efficacy of the alpha-radioimmunotherapy of ovarian cancer in mice, using different specific activities. "
11/01/2006 - "The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice. "